

Jonathan W Said

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2142876/publications.pdf>

Version: 2024-02-01

91
papers

4,248
citations

147801

31
h-index

128289

60
g-index

91
all docs

91
docs citations

91
times ranked

5548
citing authors

#	ARTICLE	IF	CITATIONS
1	CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 384-384.	1.6	4
2	HIV, pathology and epigenetic age acceleration in different human tissues. GeroScience, 2022, 44, 1609-1620.	4.6	15
3	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
4	CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2022, 40, 2543-2543.	1.6	6
5	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	3.7	10
6	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. European Urology, 2020, 77, 3-10.	1.9	18
7	RNA-Binding Protein <i>ZFP36L1</i> Suppresses Hypoxia and Cell-Cycle Signaling. Cancer Research, 2020, 80, 219-233.	0.9	40
8	Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma. Gut, 2020, 69, 630-640.	12.1	68
9	A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 563-572.	7.1	20
10	Trisomy 3, a sole recurrent cytogenetic abnormality in pediatric polymorphic post-transplant lymphoproliferative disorder (PTLD). Cancer Genetics, 2020, 248-249, 39-48.	0.4	2
11	TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. Gastroenterology, 2020, 159, 1311-1327.e19.	1.3	92
12	SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene, 2019, 38, 6196-6210.	5.9	32
13	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	12.8	21
14	Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nature Communications, 2019, 10, 1353.	12.8	39
15	Severe mosquito bite allergy: an unusual EBV+ NK cell lymphoproliferative disorder. Blood, 2019, 133, 999-999.	1.4	2
16	A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. Journal of Urology, 2018, 200, 564-572.	0.4	28
17	Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2018, 59, 321-329.	1.3	7
18	Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2018, 21, 212-220.	3.9	24

#	ARTICLE	IF	CITATIONS
19	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	1.4	97
20	The c-MYC/BMI1 axis is essential for SETDB1-mediated breast tumorigenesis. <i>Journal of Pathology</i> , 2018, 246, 89-102.	4.5	28
21	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.8	10
22	Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. <i>Blood</i> , 2018, 132, 1871-1878.	1.4	85
23	Clinical characteristics and outcomes of PTLD following intestinal transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13313.	1.6	21
24	A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 653-653.	1.6	1
25	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. <i>Journal of Experimental Medicine</i> , 2017, 214, 1371-1386.	8.5	144
26	LPS independent activation of the pro-inflammatory receptor Trem1 by C/EBP μ in granulocytes. <i>Scientific Reports</i> , 2017, 7, 46440.	3.3	9
27	Establishing ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1786-1792.	5.0	35
28	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2017, 107, 171-177.	1.0	3
29	Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 4376-4387.	7.0	46
30	Multicentric Castleman disease: consensus at last?. <i>Blood</i> , 2017, 129, 1569-1570.	1.4	3
31	BCL6 promotes glioma and serves as a therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3981-3986.	7.1	58
32	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. <i>Scientific Reports</i> , 2017, 7, 9749.	3.3	32
33	Circadian clock cryptochrome proteins regulate autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12548-12553.	7.1	84
34	Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. <i>Urology</i> , 2017, 99, 270-277.	1.0	31
35	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	1.9	83
36	Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. <i>Journal of Hematology and Oncology</i> , 2017, 10, 173.	17.0	25

#	ARTICLE	IF	CITATIONS
37	Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. <i>Oncotarget</i> , 2017, 8, 7521-7532.	1.8	37
38	Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 7-7.	1.6	0
39	Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7-7.	1.6	0
40	HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. <i>Journal of Virology</i> , 2016, 90, 8968-8983.	3.4	127
41	Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. <i>Prostate</i> , 2016, 76, 1293-1302.	2.3	51
42	Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1326-1332.	2.5	22
43	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2170-2175.	7.1	102
44	CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling. <i>Cancer Research</i> , 2016, 76, 2687-2697.	0.9	29
45	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 509-509.	1.6	0
46	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. <i>International Journal of Cancer</i> , 2015, 136, 2055-2064.	5.1	95
47	The expanding spectrum of EBV+ lymphomas. <i>Blood</i> , 2015, 126, 827-828.	1.4	19
48	Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e25-204.e33.	1.6	29
49	B-lymphoblastic transformation of mantle cell lymphoma/leukemia with "double hit" changes. <i>Journal of Hematopathology</i> , 2015, 8, 31-36.	0.4	11
50	Coexpression of cytokeratin and B cell markers "a rare finding with new implications. <i>Journal of Hematopathology</i> , 2015, 8, 95-97.	0.4	0
51	Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma. <i>Cancer Research</i> , 2015, 75, 1815-1827.	0.9	50
52	SETDB1 accelerates tumorigenesis by regulating the WNT signalling pathway. <i>Journal of Pathology</i> , 2015, 235, 559-570.	4.5	64
53	Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance. <i>Blood</i> , 2015, 126, 1029-1029.	1.4	2
54	Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). <i>Blood</i> , 2015, 126, 334-334.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Genomic landscape of liposarcoma. <i>Oncotarget</i> , 2015, 6, 42429-42444.	1.8	94
56	Burkitt Lymphoma and MYC. <i>Advances in Anatomic Pathology</i> , 2014, 21, 160-165.	4.3	16
57	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
58	Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 93-93.	1.6	0
59	Validation of the CAIX score as a prognostic biomarker for lymphatic spread and cancer-specific survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 454-454.	1.6	0
60	The role of obesity in the incidence of lymphatic spread, disease-free, and overall survival: Data from the ARISER clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 435-435.	1.6	0
61	C/EBP β Plays a Role in Immunity By Regulating Trem-1 Expression in Granulocytes. <i>Blood</i> , 2014, 124, 4100-4100.	1.4	0
62	Aggressive B-cell lymphomas: how many categories do we need?. <i>Modern Pathology</i> , 2013, 26, S42-S56.	5.5	47
63	Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8559-8559.	1.6	0
64	Diffuse Aggressive B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2009, 16, 216-235.	4.3	18
65	CEBPalpha and a Critical Circadian Clock Downstream Target Gene, PER2, Are Highly Dysregulated in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3454-3454.	1.4	0
66	Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, S1, S4-13; quiz S15.	0.3	2
67	Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study. <i>Blood</i> , 2008, 112, 476-476.	1.4	1
68	Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 4470-4470.	1.4	1
69	Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin's Lymphomas. <i>Blood</i> , 2008, 112, 4140-4140.	1.4	0
70	Immunodeficiency-related Hodgkin Lymphoma and its Mimics. <i>Advances in Anatomic Pathology</i> , 2007, 14, 189-194.	4.3	42
71	Bortezomib Is a Novel Inducer of Latent Epstein Barr Virus (EBV) in EBV+ Lymphoma Cell Lines.. <i>Blood</i> , 2006, 108, 2511-2511.	1.4	3
72	Biomarker discovery in urogenital cancer. <i>Biomarkers</i> , 2005, 10, 83-86.	1.9	29

#	ARTICLE	IF	CITATIONS
73	Active Combination Therapy of Bortezomib (Velcade) and Ibritumomab Tiuxetan (Zevalin) in an In Vivo Diffuse Large B-Cell Lymphoma Model.. Blood, 2005, 106, 2406-2406.	1.4	5
74	Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM.. Blood, 2005, 106, 114-114.	1.4	1
75	Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays.. Blood, 2005, 106, 1933-1933.	1.4	0
76	Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan in Vitro and in Vivo.. Blood, 2004, 104, 2470-2470.	1.4	3
77	Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo.. Blood, 2004, 104, 2467-2467.	1.4	3
78	Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic Biology. Human Gene Therapy, 2001, 12, 883-892.	2.7	97
79	Analysis of the CHK2 Gene in Lymphoid Malignancies. Leukemia and Lymphoma, 2001, 42, 517-520.	1.3	27
80	Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene, 2001, 20, 3301-3305.	5.9	108
81	PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. , 2000, 42, 163-171.		74
82	PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate, 2000, 42, 163.	2.3	1
83	Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate, 1999, 40, 141-149.	2.3	46
84	Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. , 1999, 40, 141.		1
85	Microsatellite instability in adult T-cell leukaemia. British Journal of Haematology, 1998, 101, 341-344.	2.5	24
86	Methylation of the p16INK4A gene in multiple myeloma. British Journal of Haematology, 1998, 101, 558-564.	2.5	50
87	Mechanisms of Growth Control of Kaposi's Sarcoma-associated Herpes Virus-associated Primary Effusion Lymphoma Cells. Blood, 1998, 91, 2475-2481.	1.4	7
88	Is Kaposi's Sarcoma-associated Herpesvirus Ubiquitous in Urogenital and Prostate Tissues?. Blood, 1997, 89, 1686-1689.	1.4	39
89	Localization of Kaposi's Sarcoma-associated Herpesvirus in Bone Marrow Biopsy Samples From Patients With Multiple Myeloma. Blood, 1997, 90, 4278-4282.	1.4	153
90	Analysis of p18INK4C in adult T-cell leukaemia and non-Hodgkin's lymphoma. British Journal of Haematology, 1997, 99, 668-670.	2.5	21

#	ARTICLE	IF	CITATIONS
91	Ultrastructural characterization of human herpesvirus 8 (Kaposi's sarcoma- associated herpesvirus) in Kaposi's sarcoma lesions: electron microscopy permits distinction from cytomegalovirus (CMV). , 1997, 182, 273-281.		48